




Patent Docket P1862R1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Daniel J. Burdick et al.  Serial No.: 10/618,178  Filed: July 11, 2003  For: LFA-1 ANTAGONIST COMPOUNDS	Group Art Unit: 1614  Examiner: NOT KNOWN  Confirmation No: 4372  <b>Customer No: 09157</b>  <b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on  January 7, 2004  Aida Gulam
---	---

REQUEST FOR A CORRECTED FILING RECEIPT

Mail Stop: Office of Initial Patent Examination  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


Attached is a copy of the Official Filing Receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested. Please make the correction as follows: Under "Domestic Priority Data as claimed by applicant," after "PAT 6,667,318," please insert--WHICH CLAIMS PRIORITY TO PROVISIONAL APPLN 60/253,682, 11/28/2000, NOW ABD--.

The correction is not due to any error by applicant and no fee is believed to be due. However, in the event that the Patent Office determines that fees are due in connection with the filing of this document, we hereby authorize the Commissioner to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,  
GENENTECH, INC.

Date: January 7, 2004

1 DNA Way  
South San Francisco, CA 94080-4990

By:   
David W. Evans  
Reg. No. \*  
Telephone No. (650) 225-1739

\* A copy of a document pursuant to 37 C.F.R. § 10.9(b) is attached as proof of the authorization of the above to prosecute the attached application. The original of this document is on file in the Office of enrollment and Discipline



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/618,178	07/11/2003	1614	822	P1862R1C1		24	1

09157  
 GENENTECH, INC.  
 1 DNA WAY.  
 SOUTH SAN FRANCISCO, CA 94080

**RECEIVED**

DEC 18 2003

GENENTECH, INC.  
 LEGAL, DEPT.

CONFIRMATION NO. 4372

FILING RECEIPT



\*OC000000011454891\*

Date Mailed: 12/10/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

**Applicant(s)**

Daniel J. Burdick, Burlingame, CA;  
 Mark S. Stanley, Pacifica, CA;  
 David Oare, Belmont, CA;  
 Mark E. Reynolds, Millbrae, CA;  
 Thomas R. Gadek, Oakland, CA;  
 James C. Marsters JR., Oakland, CA;

**Assignment For Published Patent Application**

Genentech, Inc.;

**Domestic Priority data as claimed by applicant**

This application is a CON of 09/994,546 11/26/2001 PAT 6,667,318

Foreign Applications <sup>^</sup> WHICH CLAIMS PRIORITY TO PROVISIONAL APPN 60/253,682 11/28/2000 <sup>NOW</sup> ABD <sup>^</sup>

If Required, Foreign Filing License Granted: 10/09/2003

Projected Publication Date: 03/18/2004

Non-Publication Request: No

Early Publication Request: No

**Title**

LFA-1 antagonist compounds

**Preliminary Class**

514

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).